Rare Diseases
Staying Agile to Bring Therapies to Patients with Rare Diseases
Sheila Frame
Amryt Pharma
PAO-06-022-CL-08Jun 21, 2022
Treatment
Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Castle Creek Pharmaceuticals
PR-M08-18-NI-120Aug 31, 2018
Joint Venture
RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa
RegeneRx
PR-M08-18-NI-039Aug 10, 2018